IPF AIR Study Press Release

We are delighted to present this press release from Vicore Pharma reporting the interim results of the AIR study investigating the novel angiotensin 2 receptor agonist, C21, in IPF.  The results are fantastic and suggest that C21 can actually increase FVC in patients with IPF.  This follows on very well from the findings that C21 can reduce the need for oxygen in patients with     COVID-19 pneumonitis. 

Breathing Matters has been involved with Vicore Pharma and the development of C21 for over 10 years.  We are delighted to see the fruits of these labours and are very excited and all set up to recruit our first IPF patient to the AIR study at UCLH.  If you are an IPF patient at UCLH and are interested in being recruited to the AIR Study, please speak to your consultant.

You can access the press release here.

 

Sign up to receive our news and updates

  • This form collects your name and email address so that we can keep you updated with news and information about Breathing Matters. Please check our Privacy Policy to see how we protect and manage your data.

Where there's research there's hope

Research into respiratory conditions accounts for just 2% of all the medical research funding in the UK.

Will you support respiratory research?